GlassScriptPhysician profile
Julie Ann Wallace
NPI 1871592329
$1,674.22
in general payments reported to CMS, 2019-2025
28 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.91 · 2021: $154 · 2022: $596 · 2023: $266 · 2024: $297 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.56 | 2022-2025 | Vraylar |
| Pfizer INC. | $163.81 | 2021-2025 | |
| Exact Sciences Corporation | $147.74 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $131.39 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $103.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.55 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $90.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.58 | 2021-2023 | |
| Almatica Pharma LLC | $68.18 | 2021-2022 | |
| Abbott Laboratories | $64.89 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $43.17 | 2022-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $36.75 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $35.58 | 2022 | |
| Dexcom, INC. | $33.03 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $27.60 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.33 | 2022-2025 | Arexvy, Shingrix |
| Jazz Pharmaceuticals INC. | $22.58 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.62 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $20.81 | 2021 | |
| Esperion Therapeutics, INC. | $19.28 | 2021 | |
| Vivus LLC | $17.34 | 2023 | Qsymia |
| Cranial Technologies, INC | $16.31 | 2023 | Doc Band |
| Currax Pharmaceuticals LLC | $16.30 | 2024 | Contrave, Onzetra Xsail |
| Gilead Sciences, INC. | $15.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.55 | 2022 | |
| Astellas Pharma US INC | $15.52 | 2024 | Veozah |
| Amarin Pharma, INC. | $13.61 | 2019 | |
| Seqirus USA INC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.